Remdesivir: Review of pharmacology, pre ‐clinical data and emerging clinical experience for COVID‐19
AbstractThe global pandemic of novel coronavirus disease 2019 (COVID ‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has created an urgent need for effective antivirals. Remdesivir (formerly GS‐5734) is a nucleoside analogue pro‐drug currently being evaluated in COVID‐19 clinical trials. Its unique structural features allow hig h concentrations of the active triphosphate metabolite to be delivered intracellularly and it evades proofreading to successfully inhibit viral RNA synthesis. In pre‐clinical models, remdesivir has demonstrated potent antiviral activity against diverse human...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 23, 2020 Category: Drugs & Pharmacology Authors: Sarah CJ Jorgensen, Razieh Kebriaei, Linda D Dresser Tags: REVIEW OF THERAPEUTICS Source Type: research

Combining Antidepressants with β‐Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction
ConclusionsResults of this analysis suggest that initiation of certain antidepressants was associated with an increased risk for serious medical sequelae among patients concurrently receiving β‐blockers. Greater risk was observed with antidepressants that potently inhibit the CYP2D6 enzyme, implying that increased morbidity may be mediated by a metabolic drug interaction. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 22, 2020 Category: Drugs & Pharmacology Authors: Jaekyu Shin, Nancy K. Hills, Patrick R. Finley Tags: Original Research Article Source Type: research

Evolving therapeutic options for chronic graft vs. host disease
AbstractDespite improvements in prevention and treatment of acute graft versus host disease (aGVHD), chronic GVHD remains a significant contributor to morbidity and mortality of allogeneic transplant patients. Chronic GVHD (cGVHD) remains a leading cause of late complications post ‐transplant and is impacted by donor, patient and transplant related (HCT) factors. Advances in the biologic understanding of cGVHD have provided opportunities to improve clinical interventions for prevention and treatment. Expansion of post‐transplantation cyclophosphamide (PTCy) beyond haplo‐ identical HCTs has transformed alternative don...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 22, 2020 Category: Drugs & Pharmacology Authors: Rebecca Gonzalez, Joseph Pidala Tags: SI ON STEM CELL TRANSPLANTATION Source Type: research

Delayed Initiation of Remdesivir in a COVID ‐19‐Positive Patient
We present a case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS ‐CoV‐2) in a mixed medical intensive care unit of a community teaching hospital. A previously healthy 40‐year‐old man was admitted to the hospital 3 days after the onset of coronavirus disease 2019 (COVID‐19) symptoms including dry cough, fever, and shortness of breath progressing to intub ation and increased mechanical ventilator support. A request for compassionate use remdesivir was submitted on the same hospital day as the positive COVID‐19 ...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 20, 2020 Category: Drugs & Pharmacology Authors: Emily Hillaker, Julie J. Belfer, Anamaria Bondici, Hani Murad, Lisa E. Dumkow Tags: Case Report Source Type: research

Tacrolimus Concentration ‐to‐Dose Ratios in Kidney Transplant Recipients and Relationship to Clinical Outcomes
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 18, 2020 Category: Drugs & Pharmacology Tags: Corrigendum Source Type: research

Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 18, 2020 Category: Drugs & Pharmacology Tags: Corrigendum Source Type: research

Tacrolimus Concentration ‐to‐Dose Ratios in Kidney Transplant Recipients and Relationship to Clinical Outcomes
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 18, 2020 Category: Drugs & Pharmacology Tags: Corrigendum Source Type: research

Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 18, 2020 Category: Drugs & Pharmacology Tags: Corrigendum Source Type: research

Issue Information
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 40, Issue 5, Page 373-375, May 2020. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 15, 2020 Category: Drugs & Pharmacology Tags: Issue Information Source Type: research

Importance of Initial Complete Parenteral Iron Repletion on Hemoglobin Level Normalization and Health Care Resource Utilization: A Retrospective Analysis
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 10, 2020 Category: Drugs & Pharmacology Tags: Corrigendum Source Type: research

Advances in CAR T Therapy for Hematologic Malignancies
AbstractThe introduction of chimeric antigen receptor T cell (CAR T) therapy has resulted in a paradigm shift in the management of relapsed/refractory B cell malignancies. Patients with acute lymphoblastic leukemia and non ‐Hodgkin’s lymphoma who had exhausted all meaningful treatment options now have an opportunity for long‐term remission and possibly cure. CAR T is rapidly expanding into the treatment paradigm for multiple myeloma with approvals expected in the near future. CAR T for chronic lymphocytic leukem ia may not be far behind, while CAR T studies in Hodgkin lymphoma and acute myeloid leukemia are ongoi...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 8, 2020 Category: Drugs & Pharmacology Authors: Craig W. Freyer, David L. Porter Tags: SI ON STEM CELL TRANSPLANTATION Source Type: research

Pharmacokinetics of sulfamethoxazole and trimethoprim during veno ‐venous extracorporeal membrane oxygenation: A case report
We describe a case of a 33‐year old male with severe respiratory failure due toPneumocystis jirovecii infection on a background of recently diagnosed HIV infection. He required veno ‐venous ECMO therapy for refractory respiratory failure. Intravenous sulfamethoxazole‐trimethoprim (100 mg/kg/day and 20 mg/kg/day) was administered in a 6‐hourly dosing regimen. Pre‐oxygenator, post‐oxygenator and arterial blood samples were collected post antibiotic administration and we re analyzed for total sulfamethoxazole and trimethoprim concentrations. The peak sulfamethoxazole and trimethoprim concentrations were 122 mg/L a...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 7, 2020 Category: Drugs & Pharmacology Authors: Jayesh A. Dhanani, Jeffrey Lipman, Jason Pincus, Shane Townsend, Amelia Livermore, Steven C. Wallis, Mohd H. Abdul ‐Aziz, Jason A. Roberts Tags: CASE REPORT Source Type: research

COVID ‐19: The Uninvited Guest in the Intensive Care Unit — Implications for Pharmacotherapy
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 4, 2020 Category: Drugs & Pharmacology Authors: Kathleen A. Stringer, Michael A. Puskarich, Michael T. Kenes, Robert P. Dickson Tags: Editorial Source Type: research

The Role of Scientific Publishing in the SARS ‐CoV‐2 Pandemic
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 4, 2020 Category: Drugs & Pharmacology Authors: C. Lindsay DeVane Tags: Editorial Source Type: research

COVID ‐19: The Uninvited Guest in the Intensive Care Unit — Implications for Pharmacotherapy
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 4, 2020 Category: Drugs & Pharmacology Authors: Kathleen A. Stringer, Michael A. Puskarich, Michael T. Kenes, Robert P. Dickson Tags: Editorial Source Type: research

The Role of Scientific Publishing in the SARS ‐CoV‐2 Pandemic
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 4, 2020 Category: Drugs & Pharmacology Authors: C. Lindsay DeVane Tags: Editorial Source Type: research

Systematic Review of Crizanlizumab: a New Parenteral Option to Reduce Vaso ‐occlusive Pain Crises in Patients with Sickle Cell Disease
This article reviews the evidence pertaining to crizanlizumab in SCD by searching records in Medline, Embase, and International Pharmaceutical Abstracts. Crizanlizumab, a P‐selectin inhibitor, mitigates the microvascular vaso‐occlusion in SCD. In the multi‐center, randomized, double‐blind SUSTAIN trial, a higher dose of crizanlizumab decreased the incidence of VOC by 45% and prolonged the median time to the first and second VOC. A post hoc subgroup analysis demonstrated that the proportion of patients who had no VOC incidence during the study period was greater in the crizanlizumab group, and this benefit was consi...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 29, 2020 Category: Drugs & Pharmacology Authors: Jin Han, Santosh L. Saraf, Victor R. Gordeuk Tags: REVIEW OF THERAPEUTICS Source Type: research

Combining Antidepressants with Beta ‐Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction
ConclusionsResults of this analysis suggest that initiation of certain antidepressants was associated with an increased risk for serious medical sequelae among patients concurrently receiving beta ‐blockers. Greater risk was observed with antidepressants, which potently inhibit the CYP2D6 enzyme, implying that increased morbidity may be mediated by a metabolic drug interaction. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 28, 2020 Category: Drugs & Pharmacology Authors: Jaekyu Shin, Nancy K. Hills, Patrick R. Finley Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Melatonin use in hospitalized children for non ‐anesthetic indications: A systematic review
ConclusionsThe current data suggest that melatonin is safe for use in hospitalized neonates. Melatonin may be beneficial for reducing inflammatory markers in neonatal patients with disease states and clinical sequelae that are associated with increased inflammation and oxidative stress. Melatonin, in conjunction with phototherapy, is not superior to use of vitamin D with phototherapy for treatment of neonatal jaundice. Studies in other pediatric populations are warranted. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 28, 2020 Category: Drugs & Pharmacology Authors: David Procaccini, Katie Lobner, Blair Anton, Sapna R. Kudchadkar Tags: REVIEW OF THERAPEUTICS Source Type: research

Akathisia and Newer Second ‐Generation Antipsychotic Drugs: A Review of Current Evidence
ConclusionClinicians should consider risk of akathisia when choosing a treatment option and monitor for akathisia in patients beginning therapy with an SGA or following a dose increase of the SGA. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 28, 2020 Category: Drugs & Pharmacology Authors: Constance L. Chow, Nour K. Kadouh, Jolene R. Bostwick, Amy M. VandenBerg Tags: REVIEW OF THERAPEUTICS Source Type: research

Maintenance Strategies after Hematopoietic Cell Transplantation
AbstractHematopoietic cell transplantation (HCT) is an essential component of potentially curative therapy for patients with hematologic malignancies. High dose chemotherapy with autologous (auto) stem cell rescue is used to overcome chemoresistance in multiple myeloma (MM), non ‐Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL). Alternatively, poor‐risk acute leukemias rely on the graft versus leukemia effect of allogeneic (allo) products. Long‐term remissions are feasible with both auto and allo HCT, however, disease relapse is the leading cause of death after HCT f or many patients. In recognition of this, novel t...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 28, 2020 Category: Drugs & Pharmacology Authors: Kathryn A. Culos, Katie S. Gatwood, Michael Byrne Tags: SI ON STEM CELL TRANSPLANTATION Source Type: research

Systematic review of voxelotor: a first ‐in‐class sickle hemoglobin polymerization inhibitor for management of sickle cell disease
This article reviews published data about voxelotor treatment of SCD based on a search of Medline, Embase, and International Pharmaceutical Abstracts. In a phase I/II trial, voxelotor demonstrated a dose ‐dependent pharmacokinetic and pharmacodynamic response and was well‐tolerated in healthy volunteers and patients with SCD. In a multi‐center, randomized, double‐blind, phase III trial (HOPE trial), a significantly higher percentage of patients randomized to voxelotor had increased hemoglobi n (> 1g/dL from baseline) compared to placebo. A greater reduction of hemolytic markers was also observed in the voxelotor...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 28, 2020 Category: Drugs & Pharmacology Authors: Jin Han, Santosh L. Saraf, Victor R. Gordeuk Tags: REVIEW OF THERAPEUTICS Source Type: research

Combining Antidepressants with Beta ‐Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction
ConclusionsResults of this analysis suggest that initiation of certain antidepressants was associated with an increased risk for serious medical sequelae among patients concurrently receiving beta ‐blockers. Greater risk was observed with antidepressants, which potently inhibit the CYP2D6 enzyme, implying that increased morbidity may be mediated by a metabolic drug interaction. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 28, 2020 Category: Drugs & Pharmacology Authors: Jaekyu Shin, Nancy K. Hills, Patrick R. Finley Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Melatonin use in hospitalized children for non ‐anesthetic indications: A systematic review
ConclusionsThe current data suggest that melatonin is safe for use in hospitalized neonates. Melatonin may be beneficial for reducing inflammatory markers in neonatal patients with disease states and clinical sequelae that are associated with increased inflammation and oxidative stress. Melatonin, in conjunction with phototherapy, is not superior to use of vitamin D with phototherapy for treatment of neonatal jaundice. Studies in other pediatric populations are warranted. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 28, 2020 Category: Drugs & Pharmacology Authors: David Procaccini, Katie Lobner, Blair Anton, Sapna R. Kudchadkar Tags: REVIEW OF THERAPEUTICS Source Type: research

Akathisia and Newer Second ‐Generation Antipsychotic Drugs: A Review of Current Evidence
ConclusionClinicians should consider risk of akathisia when choosing a treatment option and monitor for akathisia in patients beginning therapy with an SGA or following a dose increase of the SGA. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 28, 2020 Category: Drugs & Pharmacology Authors: Constance L. Chow, Nour K. Kadouh, Jolene R. Bostwick, Amy M. VandenBerg Tags: REVIEW OF THERAPEUTICS Source Type: research

Maintenance Strategies after Hematopoietic Cell Transplantation
AbstractHematopoietic cell transplantation (HCT) is an essential component of potentially curative therapy for patients with hematologic malignancies. High dose chemotherapy with autologous (auto) stem cell rescue is used to overcome chemoresistance in multiple myeloma (MM), non ‐Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL). Alternatively, poor‐risk acute leukemias rely on the graft versus leukemia effect of allogeneic (allo) products. Long‐term remissions are feasible with both auto and allo HCT, however, disease relapse is the leading cause of death after HCT f or many patients. In recognition of this, novel t...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 28, 2020 Category: Drugs & Pharmacology Authors: Kathryn A. Culos, Katie S. Gatwood, Michael Byrne Tags: SI ON STEM CELL TRANSPLANTATION Source Type: research

Systematic review of voxelotor: a first ‐in‐class sickle hemoglobin polymerization inhibitor for management of sickle cell disease
This article reviews published data about voxelotor treatment of SCD based on a search of Medline, Embase, and International Pharmaceutical Abstracts. In a phase I/II trial, voxelotor demonstrated a dose ‐dependent pharmacokinetic and pharmacodynamic response and was well‐tolerated in healthy volunteers and patients with SCD. In a multi‐center, randomized, double‐blind, phase III trial (HOPE trial), a significantly higher percentage of patients randomized to voxelotor had increased hemoglobi n (> 1g/dL from baseline) compared to placebo. A greater reduction of hemolytic markers was also observed in the voxelotor...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 28, 2020 Category: Drugs & Pharmacology Authors: Jin Han, Santosh L. Saraf, Victor R. Gordeuk Tags: REVIEW OF THERAPEUTICS Source Type: research

Managing COVID ‐19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroid‐sparing Immunosuppression
AbstractNovel coronavirus disease 2019 (COVID ‐19) caused by severe acute respiratory syndrome virus (SARS‐CoV‐2) has become a global healthcare crisis. The Centers for Disease Control and Prevention (CDC) lists immunocompromised patients, including those requiring immunosuppression following renal transplantation, as high‐risk for seve re disease from SARS‐CoV‐2. Treatment for other viral infections in renal transplant recipients often includes a reduction in immunosuppression, however, there are no current guidelines recommending the optimal approach to managing immunosuppression in the patients who are infec...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 27, 2020 Category: Drugs & Pharmacology Authors: Kristen M. Johnson, Julie J. Belfer, Gina R. Peterson, Mark R. Boelkins, Lisa E. Dumkow Tags: REVIEW OF THERAPEUTICS Source Type: research

Evaluation of Addition of Intravenous Metronidazole to Oral Vancomycin Therapy in Critically Ill Patients with Non ‐Fulminant Severe Clostridioides difficile Infection
BackgroundData on the impact of combination therapy (intravenous metronidazole [IV MTZ] plus oral vancomycin [PO VAN]) on clinical outcomes in intensive care unit (ICU) patients with severe non ‐fulminantClostridioides difficile infection (CDI), including NAP1 ‐positive samples, are lacking.MethodsRetrospective observational cohort of adult patients who developed CDI in the ICU diagnosed with severe non ‐fulminant CDI who received PO VAN. Patients with an order for IV MTZ started within 72 hours of PO VAN and who received at least 72 hours of combined therapy composed the combination therapy group. A subset...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 21, 2020 Category: Drugs & Pharmacology Authors: Ana D. Vega, Emily L. Heil, Alison L. Blackman, Mary Banoub, Jennifer Kristie Johnson, Surbhi Leekha, Kimberly C. Claeys Tags: Original Research Article Source Type: research

Delayed Initiation of Remdesivir in a COVID ‐19 Positive Patient
AbstractA case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS ‐CoV‐2) in a mixed medical ICU of a community teaching hospital is presented. A previously healthy 40 year‐old male was admitted to the hospital three days after the onset of coronavirus disease 2019 (COVID‐19) symptoms, including dry cough, fever, and shortness of breath progressing to intu bation and increased mechanical ventilator support. A request for compassionate use remdesivir was submitted on the same hospital day as the positive COVID‐19 PC...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 13, 2020 Category: Drugs & Pharmacology Authors: Emily Hillaker, Julie J. Belfer, Anamaria Bondici, Hani Murad, Lisa E. Dumkow Tags: CASE REPORT Source Type: research

Chloroquine and Hydroxychloroquine in the Era of SARS – CoV2: Caution on Their Cardiac Toxicity
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 13, 2020 Category: Drugs & Pharmacology Authors: Jerry L. Bauman, James E. Tisdale Tags: Editorial Source Type: research

Delayed Initiation of Remdesivir in a COVID ‐19 Positive Patient
AbstractA case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS ‐CoV‐2) in a mixed medical ICU of a community teaching hospital is presented. A previously healthy 40 year‐old male was admitted to the hospital three days after the onset of coronavirus disease 2019 (COVID‐19) symptoms, including dry cough, fever, and shortness of breath progressing to intu bation and increased mechanical ventilator support. A request for compassionate use remdesivir was submitted on the same hospital day as the positive COVID‐19 PC...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 13, 2020 Category: Drugs & Pharmacology Authors: Emily Hillaker, Julie J. Belfer, Anamaria Bondici, Hani Murad, Lisa E. Dumkow Tags: CASE REPORT Source Type: research

Chloroquine and Hydroxychloroquine in the Era of SARS – CoV2: Caution on Their Cardiac Toxicity
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 13, 2020 Category: Drugs & Pharmacology Authors: Jerry L. Bauman, James E. Tisdale Tags: Editorial Source Type: research

Issue Information
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 40, Issue 4, Page 271-273, April 2020. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 11, 2020 Category: Drugs & Pharmacology Tags: Issue Information Source Type: research

Recommended Revisions to the National SEP ‐1 Sepsis Quality Measure: A commentary by the Society of Infectious Diseases Pharmacists on the Infectious Diseases Society of America Position Paper
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 40, Issue 4, Page 368-371, April 2020. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 11, 2020 Category: Drugs & Pharmacology Authors: Emily L. Heil, Samuel L. Aitken, David E. Nix, Richard Drew, Warren E. Rose, Susan L. Davis, Julie Ann Justo, Douglas N. Fish, Jason M. Pogue, on Behalf of the Society of Infectious Diseases Pharmacists Tags: Invited Commentary Source Type: research

Issue Information
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 40, Issue 4, Page 271-273, April 2020. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 11, 2020 Category: Drugs & Pharmacology Tags: Issue Information Source Type: research

Recommended Revisions to the National SEP ‐1 Sepsis Quality Measure: A commentary by the Society of Infectious Diseases Pharmacists on the Infectious Diseases Society of America Position Paper
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 40, Issue 4, Page 368-371, April 2020. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 11, 2020 Category: Drugs & Pharmacology Authors: Emily L. Heil, Samuel L. Aitken, David E. Nix, Richard Drew, Warren E. Rose, Susan L. Davis, Julie Ann Justo, Douglas N. Fish, Jason M. Pogue, on Behalf of the Society of Infectious Diseases Pharmacists Tags: Invited Commentary Source Type: research

Therapeutic Potential for Tetracyclines in the Treatment of COVID ‐19
AbstractCurrently there is a race against time to identify prophylactic and therapeutic treatments against COVID ‐19. Until these treatments are developed, tested and mass produced, it might be prudent to look into existing therapies that could be effective against this virus. Based on the available evidence we believe that tetracyclines may be effective agents in the treatment of COVID‐19. Tetracyclines ( e.g. tetracycline, doxycycline, and minocycline) are highly lipophilic antibiotics that are known to chelate zinc compounds on matrix metalloproteinases (MMPs)1. Coronaviruses are also known to heavily rely on host M...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 8, 2020 Category: Drugs & Pharmacology Authors: Mohit Sodhi, Mahyar Etminan Tags: LETTER TO THE EDITOR Source Type: research

COVID ‐19: Important Therapy Considerations and Approaches in this Hour of Need
AbstractWe are living in unprecedented times. While we had near pandemic events in the recent past with SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome), we have never experienced anything like coronavirus (COVID ‐19), also known as SARS‐CoV‐2 infection, since the Spanish flu. In contrast to the Spanish flu where medical care was limited, we are equipped to combat COVID‐19 but there is considerable work ahead with many uncertainties. At this critical time, we must come together as one united country and world to stop the spread and provide the best care possible for individuals w...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 8, 2020 Category: Drugs & Pharmacology Authors: Thomas P. Lodise, Michael J. Rybak Tags: EDITORIAL Source Type: research

Considerations for statin therapy in patients with COVID ‐19
AbstractCurrent coronavirus pandemic named coronavirus disease 2019 (COVID ‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). SARS‐CoV‐2 is the third coronavirus outbreak during the current century after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses.1 Acute respiratory distress syndrome (ARDS) is an immunopathologic event and main cause of death following COVID ‐19. The main mechanism of ARDS is uncontrolled systemic inflammatory response and cytokine storm following release of proinflammatory cytokines (such as interferons (IFN), in...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 8, 2020 Category: Drugs & Pharmacology Authors: Simin Dashti ‐Khavidaki, Hossein Khalili Tags: LETTER TO THE EDITOR Source Type: research

COVID ‐19: The Uninvited Guest in the Intensive Care Unit (ICU) Implications for Pharmacotherapy
AbstractAs the number of cases of COVID ‐19 (SARS‐CoV‐2) rise in the United States (US), the number of severe cases (those requiring ICU admission) rise with it. Initially, the estimate for severe cases was approximated at 5% based on experience from China.1, 2 However, the World Health Organization ’s (WHO) estimate from China for severe and critical cases is near 20% (Table).3 The primary clinical feature of COVID ‐19 is pneumonia, the severity of which directs the clinical course; it has been estimated that, of patients admitted to the ICU, up to half may require either invasive or non‐invasive ventilato...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 8, 2020 Category: Drugs & Pharmacology Authors: Kathleen A. Stringer, Michael A Puskarich, Michael T. Kenes, Robert P. Dickson Tags: EDITORIAL Source Type: research

Therapeutic Potential for Tetracyclines in the Treatment of COVID ‐19
AbstractCurrently there is a race against time to identify prophylactic and therapeutic treatments against COVID ‐19. Until these treatments are developed, tested and mass produced, it might be prudent to look into existing therapies that could be effective against this virus. Based on the available evidence we believe that tetracyclines may be effective agents in the treatment of COVID‐19. Tetracyclines ( e.g. tetracycline, doxycycline, and minocycline) are highly lipophilic antibiotics that are known to chelate zinc compounds on matrix metalloproteinases (MMPs)1. Coronaviruses are also known to heavily rely on host M...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 8, 2020 Category: Drugs & Pharmacology Authors: Mohit Sodhi, Mahyar Etminan Tags: LETTER TO THE EDITOR Source Type: research